Source - SMW
Cambridge Cognition Holdings has signed  two major contracts using the company's CANTAB Connect technology.   The contracts totalling US$3.67million are with US biopharmaceutical companies for late stage clinical trials and will contribute US$1.07 million to reported revenue in the second half of 2016. 

The award of the contracts was expected and so the outlook for the current year remains unchanged.




Related Charts

Cambridge Cognition Holdings (COG)

0.00p (0.00%)
delayed 18:15PM